CoChat

The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review

Open access
Bessonova, Leona, Ogden, Kristine, Doane, Michael J, O'Sullivan, Amy K, Tohen, Mauricio · 2020 · ClinicoEconomics and Outcomes Research

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

Abstract

Bipolar disorder (BD) is a mood disorder with subtypes characterized by episodes of mania, hypomania, and/or depression. BD is associated with substantial economic burden, and the bipolar I disorder (BD-I) subtype is associated with high medical costs. This review further evaluated the economic burden of BD and BD-I in the United States (US), describing health-care resource utilization (HCRU) and sources of direct medical and indirect costs. Data were obtained from systematic searches of MEDLINE ® , EMBASE ® , and National Health Service Economic Evaluation Database. Citations were screened to identify primary research studies (published 2008– 2018) on the economic burden of BD/BD-I or its treatment in real-world settings. Reported costs were converted to 2018 US dollars. Of identified abstracts (N=4111), 56 studies were included. The estimated total annual national economic burden of BD/BD-I was more than $195 billion, with approximately 25% attributed to direct medical costs. Individuals with BD/BD-I used health-care services more frequently and had higher direct medical costs than matched individuals without the disease. Drivers of higher direct costs included frequent psychiatric interventions, presence of comorbid medical/psychiatric conditions, and both suboptimal medication adherence and clinical management. Indirect costs (eg, unemployment, lost work productivity for patients/caregivers) accounted for 72– 80% of the national economic burden of BD/BD-I. Different definitions for study populations and cost categories limited comparisons of economic outcomes. This review builds on existing literature describing the economic burden of BD and confirmed cost drivers of BD/BD-I. Improved clinical management of BD/BD-I and associated comorbidities, together with better medication adherence, may reduce health-care costs and improve patient outcomes. Keywords: cost of illness, health care costs, indirect costs, mania, mood disorder, resource utilization

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ceor.s259338

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA diagram showing the literature search process. Notes: The 2529 records excluded prior to title/abstract review were eliminated electronically by identifying duplicate citations (eg, records with duplicate identifiers or citation data fields) and publications indexed for excluded types of publications (eg, randomized controlled trials, case reports). The step “articles retrieved from other sources” refers to papers identified from bibliographic review and other known, relevant research papers. Abbreviations: BOI, burden of illness; NHS EED, National Health Service Economic Evaluation Database; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 1 PRISMA diagram showing the literature search process. Notes: The 2529 records excluded prior to title/abstract review were eliminated electronically by identifying duplicate citations (eg, records with duplicate identifiers or citation data fields) and publications indexed for excluded types of publications (eg, randomized controlled trials, case reports). The step “articles retrieved from other sources” refers to papers identified from bibliographic review and other known, relevant research papers. Abbreviations: BOI, burden of illness; NHS EED, National Health Service Economic Evaluation Database; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. Rhee, 2020, Am J Psychiatry, appiajp202019091000
  2. Baldessarini, 2008, Psychiatr Serv, 59, 1175, 10.1176/ps.2008.59.10.1175 · DOI · Paper page
  3. Pelletier, 2013, Am J Pharm Benefits, 5, e73
  4. Chatterton, 2008, P T, 33, 15
  5. Wright, 2016, J Manag Care Spec Pharm, 22, 1330
  6. Stensland, 2010, J Ment Health Policy Econ, 13, 87
  7. Seabury, 2014, Am J Manag Care, 20, e52

Cited by

See all 172

Metadata

Authors
Bessonova, L., Ogden, K., Doane, M. J., O'Sullivan, A. K., & Tohen, M.
Affiliations
  • Alkermes (United States) (US)
  • Worldwide Clinical Trials (United States) (US)
  • University of New Mexico (US)
Corresponding author
Bessonova, Leona
Venue
ClinicoEconomics and Outcomes Research
Published
2020-09
Volume
Volume 12
Pages
481-497
ISSN
1178-6981 (ISSN-L)
OpenAlex
W3083267042
Cited by
147
References
78
Citations by year
2026: 19 · 2025: 29 · 2024: 29 · 2023: 29 · 2022: 28 · 2021: 12 · 2020: 1
FWCI
2.90
Type
journal article
Language
en
Open access
Locations
  • ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
bipolar disorder, bipolar I disorder, economic burden, healthcare resource utilization, direct medical costs, indirect costs, productivity loss, medication adherence, comorbidities, mania, mood disorders, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.